Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation reports developments in medical research programs focused on traumatic brain injury, PTSD, suicide ideation, dialysis-borne neuropathy and pruritus. The company’s updates describe its proprietary nasal spray approach for post-head-trauma treatment, its LDX compound, and work with Athena GTX, Athena Telemedicine Partners and scientists at Mississippi State University.
Recurring news also covers Halberd’s NeuroSense AI acquisition and behavioral intelligence platform, which combines multi-modal behavioral data with artificial intelligence for TBI research and clinical assessment. Other company updates address patent-related assets, government-contract efforts, private funding discussions, and OTC public-company communications.
Halberd Corp (OTC PINK:HALB) has partnered with GreenBioAZ, Inc. for laboratory testing of its patent pending Radio Frequency (RF) technology aimed at eliminating infectious disease pathogens like SARS-CoV-2. The process involves using an Antibody-Metallic Moiety Conjugate to target pathogens, converting electromagnetic waves into thermal energy to eradicate viral particles without harming healthy cells. Successful trials could pave the way for future treatments. Halberd emphasizes that these tests represent critical advancements towards developing commercially viable therapies.
Halberd Corporation (OTC PINK: HALB) announced promising results for its new patent-pending SARS-CoV-2 monoclonal antibody, demonstrating potent effects against the virus's spike protein. CEO William Hartman indicated that further details will emerge within two days, exploring its potential for prevention, diagnosis, and treatment. The company holds exclusive rights to several COVID-19 treatment-related patents. As of now, the number of outstanding shares remains at 317,721,539.
Summary not available.
Halberd Corporation (OTC PINK: HALB) CEO William A. Hartman discussed recent achievements and future goals in a Money TV interview. Key developments include three issued patents, six provisional patent applications, and the creation of two unique Covid-19 antibodies. The company is developing a nasal spray as an alternative to vaccines and a rapid diagnostic test. Funding plans involve partnerships with pharmaceutical firms and potential foreign market listings. The company is committed to addressing Covid-19 while maintaining compliance with OTC Market regulations.
Halberd Corp. (OTC PINK: HALB) announced the filing of a provisional patent for a new method aimed at eradicating Covid-19 from infected blood using an extracorporeal treatment process. The novel technique involves exposing blood to a specific radio frequency that targets a unique conjugate antibody designed to bind with the virus. This treatment reportedly presents fewer side effects compared to conventional methods. Halberd maintains its focus on complementary Covid-19 initiatives, including a nasal spray and rapid diagnostic tests.
Halberd Corporation (OTC PINK: HALB) announced a new patent-pending Covid-19 fluorescent antibody aimed at rapid virus detection. CEO William A. Hartman discussed the advantages of this test during a Money TV interview, highlighting its potential for real-time monitoring of Covid-19 status, in contrast to existing passports. The test could significantly benefit the travel and entertainment industries. Moreover, Halberd is developing a nasal spray as both a preventive and therapeutic option against Covid-19, while also working on new developments under provisional patents.
Halberd Corporation (OTC PINK:HALB) has developed a second monoclonal antibody targeting COVID-19 antigens, potentially enhancing the efficacy of their nasal spray treatment. Dr. Mitchell S. Felder filed a provisional patent for this innovation, which aims to reduce viral load and alleviate COVID-19 symptoms. Halberd’s recent advancements reportedly double the performance of their existing antibody. The company plans to expedite research towards animal and human testing to demonstrate safety and efficacy. Currently, there are 317,721,539 outstanding shares.
Halberd Corporation (OTC PINK: HALB) CEO William A. Hartman discussed recent achievements and strategic initiatives in an interview on Money TV. Halberd has partnered with Arizona State University for research and is focused on developing Covid-19 antibodies and related technologies. The company has filed provisional patents for innovative treatments and maintains a debt-free status. Hartman also highlighted potential applications for their technology in various diseases and introduced a prototype for an Anti-Addiction Patch. Halberd aims for significant market success amidst the ongoing pandemic challenges.
Halberd Corporation (OTC PINK: HALB) has announced the development of a new class of anti-Spike protein monoclonal antibodies targeting Covid-19, in collaboration with Arizona State University. They are in the process of filing joint patent applications for this discovery. The engineered antibodies may enable rapid detection of the virus in various samples and on surfaces. This advancement aims to enhance early identification and treatment, potentially curbing the virus's spread. Halberd's CTO highlighted the progress, signaling more patent applications to follow.
Halberd Corporation (OTC PINK: HALB) announced significant advancements in COVID-19 research through collaboration with Arizona State University. Researchers have successfully produced an anti-Spike protein monoclonal antibody targeting the virus, with plans for patent protections. Potential applications include a preventative, diagnostic, and therapeutic treatment. The company aims to provide ongoing updates on the progress of this vital research.